{
    "clinical_study": {
        "@rank": "136350", 
        "arm_group": [
            {
                "arm_group_label": "Arm 2: Cyclophosphamide 3 gms/m(2)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2)."
            }, 
            {
                "arm_group_label": "Arm 1: 1.5 gms/m(2) Cyclophosohamide", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2)."
            }
        ], 
        "brief_summary": {
            "textblock": "No prospective randomized trials have evaluated the most efficacious dose of\n      cyclophosphamide to mobilize autologous stem cells.  We previously demonstrated that the\n      time to collection of autologous hematopoietic stem cells is 10-12 days following the one\n      dose of cyclophosphamide and daily G-CSF (granulocyte-colony stimulating factor).9 This\n      prospective randomized trial is designed to determine if a lower dose of cyclophosphamide\n      (1.5 gm/m2) will be as efficacious as the intermediate dose (3 gm/m2), based on cell number\n      collected, number of apheresis required and resource utilization."
        }, 
        "brief_title": "Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hematologic Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This prospective randomized trial is designed to determine if a lower dose of\n      cyclophosphamide (1.5 gm/m2) will be as efficacious as the intermediate dose (3 gm/m2),\n      based on cell number collected, number of apheresis required and resource utilization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients must have a pathologic diagnosis of one of the following malignancies:\n\n        Non-Hodgkin's Lymphoma, including B- and T-cell lymphoma Multiple Myeloma or another\n        plasma cell dyscrasia (Waldenstrom, Amyloidosis)\n\n          -  The patient must be approved for transplant by the treating Transplant physician.\n\n          -  This must be the patient's FIRST mobilization attempt.\n\n          -  Patients are eligible if an autologous transplant is planned within approximately 12\n             months from the time of collection of cells.\n\n          -  Prior Treatment: No previous cytotoxic chemotherapy within 4 weeks prior to\n             initiation of therapy. (This does not include  immunomodulatory drugs (IMiDs),\n             proteasome inhibitors, monoclonal antibodies or steroids.)\n\n          -  No radiation within 4 weeks of mobilization attempt.\n\n          -  Age >18, and < 75 years\n\n          -  No significant co-morbid medical or psychiatric illness that would significantly\n             compromise the patient's clinical care and chances of survival.\n\n          -  Informed consent must be signed prior to the treatment. Patients must willingly\n             consent after being informed of the procedure to be followed, the nature of the\n             therapy, alternatives, potential benefits, side effects, risks and discomforts.\n             (Human protection committee approval of this protocol and a consent form is\n             required.)\n\n        Exclusion Criteria:\n\n          -  Medical, social, or psychological factors that would prevent the patient from\n             receiving or cooperating with the full course of therapy.\n\n          -  Documented hypersensitivity to any of the drugs used in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139280", 
            "org_study_id": "D13179"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 2: Cyclophosphamide 3 gms/m(2)", 
                "Arm 1: 1.5 gms/m(2) Cyclophosohamide"
            ], 
            "description": "Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.", 
            "intervention_name": "Cyclophosphamide", 
            "intervention_type": "Drug", 
            "other_name": [
                "Endoxan", 
                "Cytoxan", 
                "Neosar", 
                "Procytox", 
                "Revimmune", 
                "Cytophosphane"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cyclophosphamide", 
            "Hematopoietic", 
            "Stem Cell", 
            "Mobilization", 
            "Hematologic Malignancy"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756"
                }, 
                "name": "Dartmouth Hitchcock Medical Center"
            }, 
            "investigator": {
                "last_name": "Kenneth Meehan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Trial Examining Low- or Intermediate-Dose Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy", 
        "other_outcome": {
            "description": "Determine the post-transplant engraftment of neutrophils and platelets. 2.3.2 Qualitative and quantitative analyses of mobilized lymphocytes (Elective-pending funding).", 
            "measure": "Hematological Laboratory Determinations", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed approximately 6 weeks following initiation of treatment"
        }, 
        "overall_contact": {
            "email": "eryn.m.bagley@hitchcock.org", 
            "last_name": "Eryn Bagley", 
            "phone": "603-650-4035"
        }, 
        "overall_contact_backup": {
            "email": "Kate.L.Wilcox@hitchcock.org", 
            "last_name": "Kate Wilcox, RN", 
            "phone": "(603) 650-6782"
        }, 
        "overall_official": {
            "affiliation": "Dartmouth-Hitchcock Medical Center", 
            "last_name": "Kenneth Meehan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To define the primary objective, we will identify the number and types of cells collected within the apheresis products and characterize the details of the apheresis process.", 
            "measure": "Cyclophosphamide Dose", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139280"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Resources used during the mobilization and apheresis processes will be captured. Resources include:\nTransfusions of red blood cells\nTransfusion of platelets\nHospitalizations\nIncidence of febrile neutropenia", 
            "measure": "Resource Utilization", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed approximately 6 weeks following initiation of treatment"
        }, 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}